Powerful bleed protection
Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.
Alhemo® offers bleed prevention with proven results
Results from a clinical trial with people who have hemophilia B with inhibitors or hemophilia A with inhibitors
Primary study results:
Treated spontaneous and traumatic bleeds
Study design
Clinical study of Alhemo® included people ages 12 years and older who had hemophilia A with inhibitors (80 people) and hemophilia B with inhibitors (53 people) who were treated with either bypassing agents on demand (at least 24 weeks) or Alhemo® once-daily prophylaxis (at least 32 weeks).
Discover lower target joint bleed rate and more bleed-free patients
88
%
lower target joint bleed ratea
Supportive secondary study result. Average target joint annual bleed rate of 0.1 with Alhemo® (33 people) vs 1.1 with no prophylaxis (19 people)
64
%
had zero bleedsb
in 24 weeks for people on Alhemo® prophylaxis (21 people) vs 10.5% for no prophylaxis (2 people)
Additional assessment study result
aTreated target joint bleeds.
bPatients with zero treated bleeds within first 24 weeks.
I can’t remember the last time I had a bleed.
–Royal
Individual results may vary. It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding.
Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk.
Jericho lives with hemophilia A with inhibitors and uses Alhemo®
Safety confirmed in multiple clinical trials
people in clinical trials,
including 133 males with hemophilia with inhibitors
320 males with hemophilia A with and without inhibitors and hemophilia B with and without inhibitors received at least one dose of Alhemo® as routine prophylaxis. 52 people with inhibitors were previously treated with on demand therapy and were randomized to receive on demand treatment with bypassing agents (19 people) or Alhemo® prophylaxis (33 people).
thromboembolic events
in the clinical trial of people with hemophilia with inhibitors, after trial restarta
Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots during treatment with Alhemo® if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision.
routine liver monitoring required
boxed warning
aThe explorer7 and explorer8 clinical trials were temporarily paused because 3 patients experienced 5 nonfatal TEs. In response, a plan was put in place that included deploying a laboratory developed test to measure concizumab-mtci levels in order to individualize dosing, as well as guidance around how to treat breakthrough bleeds.
Jericho lives with hemophilia A with inhibitors and uses Alhemo®
All bypassing agents can be used to treat breakthrough bleeds
Alhemo® does not treat bleeds. Your healthcare provider may prescribe a bypassing agent to use if you experience a breakthrough bleed. Follow your healthcare provider’s instructions regarding when to use on-demand bypassing agents and the recommended dose and schedule for breakthrough bleeds.
In the randomized arms of the clinical trial of people with inhibitors, injection site reactions were the most common adverse reactions, reported in 6 out of 33 people (18%) using Alhemo®, followed by hives, reported in 2 out of 33 people (6%).
Majority of injection site reactions were mild.
An allergic reaction in 1 patient (3%) led to stopping Alhemo® treatment.
Dosing and administration
Discover Alhemo®’s personalized dosing and administration steps.
Connect with us!
Want to learn more about Alhemo®? Get important email updates, information about patient support programs, and more.
